David Mott has served on Ardelyx’s board of directors since March 2009 and has been the chairperson of the board of directors since March 2014. David is currently a private investor through Mott Family Capital.
From September 2008 to February 2020, David served as a general partner of New Enterprise Associates (NEA), an investment firm focused on venture capital and growth equity investments, where he led the healthcare investing practice.
Prior to joining NEA, David worked at MedImmune, a biotechnology company and subsidiary of AstraZeneca, and served in numerous roles during his tenure, including president and chief executive officer, chief financial officer, and president and chief operating officer. During that time, David also served as executive vice president of AstraZeneca, following AstraZeneca Plc’s acquisition of Medimmune in June 2007.
Earlier in his career, he was a vice president in the healthcare investment banking group at Smith Barney, Harris Upham & Co. Inc.
David serves as the chairperson of the board of directors for Adaptimmune, and Mersana Therapeutics, and serves on the board of directors of Novavax. Dave is also Chair of the Board for Adaptimmune and Mersana and is a member of the board for Novovax.
He earned a B.A. in Economics and Government from Dartmouth College.
What is David M. Mott's net worth?
The estimated net worth of David M. Mott is at least $17.15 million as of June 16th, 2025. Mr. Mott owns 2,896,871 shares of Ardelyx stock worth more than $17,149,476 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Mott may own. Learn More about David M. Mott's net worth.
How do I contact David M. Mott?
Has David M. Mott been buying or selling shares of Ardelyx?
David M. Mott has not been actively trading shares of Ardelyx during the last quarter. Most recently, on Monday, June 16th, David M. Mott bought 200,000 shares of Ardelyx stock. The stock was acquired at an average cost of $3.63 per share, with a total value of $726,000.00. Following the completion of the transaction, the director now directly owns 2,896,871 shares of the company's stock, valued at $10,515,641.73. Learn More on David M. Mott's trading history.
Who are Ardelyx's active insiders?
Ardelyx's insider roster includes Robert Blanks (Insider), Eric Foster (Chief Commercial Officer), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Mike Kelliher (Insider), David Mott (Director), Michael Raab (CEO), Justin Renz (Chief Financial & Operations Officer), Susan Rodriguez (Insider), David Rosenbaum (Insider), Scott Sandell (Major Shareholder), and Laura Williams (Chief Medical Officer). Learn More on Ardelyx's active insiders.
Are insiders buying or selling shares of Ardelyx?
In the last year, Ardelyx insiders bought shares 7 times. They purchased a total of 1,371,406 shares worth more than $5,780,176.94. In the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 580,304 shares worth more than $3,050,503.57. The most recent insider tranaction occured on November, 21st when insider Elizabeth A Grammer sold 5,995 shares worth more than $33,212.30. Insiders at Ardelyx own 4.8% of the company.
Learn More about insider trades at Ardelyx. Information on this page was last updated on 11/21/2025.
